Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETDB1 | Q15047 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 4/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306128 | 0.79 | MAPT (0.47) | SETDB1P2RX7 | |
| Hydrochloric Acid SCHEMBL1019729 | 0.78 | NAAA (0.42) | NAAAIDH1FPR1FPR2AKR1C3 | |
| SCHEMBL1263239 | 0.77 | NAAA (0.40) | NAAAIDH1FPR1FPR2AKR1C3 | |
| SCHEMBL23486784 | 0.74 | FPR1 (0.42) | FPR1FPR2PKM | |
| SCHEMBL29758148 | 0.73 | KMT2A (0.53) | NAAAIDH1FPR1FPR2 | |
| SCHEMBL29758149 | 0.73 | KMT2A (0.53) | NAAAIDH1FPR1FPR2 | |
| SCHEMBL23466566 | 0.73 | KMT2A (0.53) | NAAAIDH1FPR1FPR2 | |
| SCHEMBL4223320 | 0.72 | HTR1A (0.46) | NAAA | |
| SCHEMBL12397945 | 0.70 | ADRA1D (0.57) | — | |
| SCHEMBL20957065 | 0.70 | NOS2 (0.43) | SETDB1EPHX2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271624-B9 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2271624-B1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-8481569-B2 | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | ADRA1D, ADRB1, ADRB2 | SETDB1 2383/4885NAAA 4061/4885IDH1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.